On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression

Natalie Gukasyan

doi:10.1016/j.medj.2022.12.003

On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression

Natalie Gukasyan

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression¹ suggest modest efficacy but raise concerns about potential for serious adverse effects. The study highlights the need for rigorous assessment of blinding integrity, expectancy, and further study of factors that may contribute to risk in vulnerable populations.

Original language	English (US)
Pages (from-to)	8-9
Number of pages	2
Journal	Med
Volume	4
Issue number	1
DOIs	https://doi.org/10.1016/j.medj.2022.12.003
State	Published - Jan 13 2023

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.medj.2022.12.003

Cite this

@article{e729abf05cd5482cb878fd2ceff81146,

title = "On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression",

abstract = "Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression1 suggest modest efficacy but raise concerns about potential for serious adverse effects. The study highlights the need for rigorous assessment of blinding integrity, expectancy, and further study of factors that may contribute to risk in vulnerable populations.",

author = "Natalie Gukasyan",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2023",

month = jan,

day = "13",

doi = "10.1016/j.medj.2022.12.003",

language = "English (US)",

volume = "4",

pages = "8--9",

journal = "Med",

issn = "2666-6359",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression

AU - Gukasyan, Natalie

PY - 2023/1/13

Y1 - 2023/1/13

N2 - Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression1 suggest modest efficacy but raise concerns about potential for serious adverse effects. The study highlights the need for rigorous assessment of blinding integrity, expectancy, and further study of factors that may contribute to risk in vulnerable populations.

AB - Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression1 suggest modest efficacy but raise concerns about potential for serious adverse effects. The study highlights the need for rigorous assessment of blinding integrity, expectancy, and further study of factors that may contribute to risk in vulnerable populations.

UR - https://www.scopus.com/pages/publications/85146355300

UR - https://www.scopus.com/pages/publications/85146355300#tab=citedBy

U2 - 10.1016/j.medj.2022.12.003

DO - 10.1016/j.medj.2022.12.003

M3 - Comment/debate

C2 - 36640755

AN - SCOPUS:85146355300

SN - 2666-6359

VL - 4

SP - 8

EP - 9

JO - Med

JF - Med

IS - 1

ER -

On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this